These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis. Huang Q; Liao Z; Liu X; Xia Y; Wang J Int Urol Nephrol; 2023 Feb; 55(2):325-334. PubMed ID: 35960479 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial. Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804 [TBL] [Abstract][Full Text] [Related]
7. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nangaku M; Farag YMK; deGoma E; Luo W; Vargo D; Khawaja Z Nephrol Dial Transplant; 2020 Jul; ():. PubMed ID: 32719868 [TBL] [Abstract][Full Text] [Related]
8. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non-Dialysis-Dependent CKD: A Post Hoc Regional Analysis of the PRO Winkelmayer WC; Arnold S; Burke SK; Chertow GM; Eckardt KU; Jardine AG; Lewis EF; Luo W; Matsushita K; McCullough PA; Minga T; Parfrey PS Kidney Med; 2023 Jul; 5(7):100666. PubMed ID: 37427293 [TBL] [Abstract][Full Text] [Related]
9. Safety Endpoints With Vadadustat Versus Darbepoetin Alfa in Patients With Non Parfrey PS; Burke SK; Chertow GM; Eckardt KU; Jardine AG; Lewis EF; Luo W; Matsushita K; McCullough PA; Minga T; Winkelmayer WC Kidney Med; 2023 Jul; 5(7):100667. PubMed ID: 37427292 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. Chertow GM; Pergola PE; Agarwal R; Block GA; Farag YMK; Jardine AG; Koury MJ; Luo W; Khawaja Z; Lewis EF; Matsushita K; McCullough PA; Parfrey PS; Wittes J; Walters KA; Tseng C; Lin T; Sarnak MJ; Vargo DL; Winkelmayer WC; Eckardt KU Am Heart J; 2021 May; 235():1-11. PubMed ID: 33129989 [TBL] [Abstract][Full Text] [Related]
12. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study. Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482 [TBL] [Abstract][Full Text] [Related]
13. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan. Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393 [TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Vadadustat Once Daily and Three Times Weekly in Patients With Dialysis-Dependent CKD With Anemia. Kooienga L; Burke S; Kathresal A; Luo W; Yang Z; Zhang Z; Zwiech R; Hernandez GT Kidney360; 2024 Nov; 5(11):1652-1661. PubMed ID: 39231617 [No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial. Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T Am J Nephrol; 2021; 52(10-11):871-883. PubMed ID: 34569489 [TBL] [Abstract][Full Text] [Related]
17. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Koury MJ; Agarwal R; Chertow GM; Eckardt KU; Fishbane S; Ganz T; Haase VH; Hanudel MR; Parfrey PS; Pergola PE; Roy-Chaudhury P; Tumlin JA; Anders R; Farag YMK; Luo W; Minga T; Solinsky C; Vargo DL; Winkelmayer WC Am J Hematol; 2022 Sep; 97(9):1178-1188. PubMed ID: 35751858 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Xiong L; Zhang H; Guo Y; Song Y; Tao Y Front Pharmacol; 2021; 12():795214. PubMed ID: 35115942 [No Abstract] [Full Text] [Related]
19. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Agarwal R; Anand S; Eckardt KU; Luo W; Parfrey PS; Sarnak MJ; Solinsky CM; Vargo DL; Winkelmayer WC; Chertow GM Am J Nephrol; 2022; 53(10):701-710. PubMed ID: 36450264 [TBL] [Abstract][Full Text] [Related]
20. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies. Nangaku M; Ueta K; Nishimura K; Sasaki K; Hashimoto T Clin Exp Nephrol; 2024 May; 28(5):391-403. PubMed ID: 38530490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]